Growth factor binding molecules

Details Growth factor binding molecules Growth factor binding molecules

2005-09-14

2009-12-15

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S009100, C514S018700, C514S717000, C514S721000, C530S330000, C568S584000, C568S585000, C568S586000

Reexamination Certificate

active

07632805

ABSTRACT:
Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In one embodiment a platelet-derived growth factor binding molecule is disclosed that is used to inhibit tumor growth and angiogenesis in solid tumors.

REFERENCES:
patent: 5457113 (1995-10-01), Cullinan et al.
patent: 5770380 (1998-06-01), Hamilton et al.
patent: 6262257 (2001-07-01), Gale et al.
patent: 2003/0118589 (2003-06-01), Sebti et al.
patent: 2005/0197401 (2005-09-01), Sebti et al.
patent: WO 01/70930 (2001-09-01), None
patent: WO 03/059925 (2003-07-01), None
patent: WO 2005/072779 (2005-08-01), None
Hagedom et al. “A Short Peptide Domain of Platelet Factor 4 Blocks Angiogenic Key Events Induced by FGF-2” The FASEB Journal. vol. 15, Mar. 2001, pp. 550-552.
Bawa et al. ‘A Single Amion Acid Substitution in MSH5 Results in DNA Alkylation Tolerance’ Gene. vol. 315, 2003, pp. 177-182.
Rudinger, J. (1976). Peptide Hormones (ed. J.A. Parsons). University Park Press. Baltimore. pp. 1-7.
Dermer, Gerald. “Another Anniversary for the War on Cancer.” Bio/Technology, vol. 12. Mar. 1994.
Gura, Trisha. “Systems for Identifying New Drugs are Often Faulty.” Science, vol. 278, pp. 1041-1042. Nov. 1997.
Golden, Fredrick. “Of Mice and Men: Don't Blame the Rodents” Time, pp. 26. May 18, 1998.
Veggeberg, Scott. ‘Fighting Cancer With Angiogenesis Inhibitors’ The Scientist, vol. 16, No. 11, May 2002, pp. 1-5. accessible via “http://www.the-scientist.com”.
Black, Harvey ‘Angiogenesis—Promoting and Blocking—Comes Into Focus’ The Scientist, vol. 12, No. 9, Apr. 1998, pp. 1-4. Accessible via “http://www.the-scientist.com”.
Hogquist et al. “T Cell Receptor Antagonist Peptides induce postivie selection,” Cell, Cell Press Cambridge, NA, US, vol. 76, No. 1. Jan. 1994, pp. 17-27.
Bradely et al. “Limits of Cooperativeity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogus Alanine Substitutions in Each Repeat.” J. Mol. Biol. vol. 324, 202, pp. 373-386.
Andersson, M. et al. “Involvement of loop 2 of platelet-derived growth factor-AA and -BB in receptor binding”Growth Factors, 1995, 12:159-164.
Bergers, G. et al. “Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase Inhibitors”J Clin Invest, 2003, 111:1287-1295.
Dvorak H.F. et al. “Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis”Curr Top Microbiol Immunol, 1999, 237:97-132.
Dvorak, H.F. “Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy”J Clin Oncol, 2002, 20:4368-4380.
Eriksson, U. and Alitalo, K. “Structure, expression and receptor-binding properties of novel vascular endothelial growth factors”Curr Top Microbiol Immunol, 1999, 237:41-57.
Ferrara, N. “Vascular endothelial growth factor: molecular and biological aspects”Curr Top Microbiol Immunol, 1999, 237:1-30.
Ferrara, N. “Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications”Semin Oncol, 2002, 29:10-14.
Jain, R.K. “Tumor angiogenesis and accessibility: role of vascular endothelial growth factor”Semin Oncol, 2002, 29:3-9.
Kerbel, R.S. “Tumor angiogenesis: past, present and the near future”Carcinogenesis, 2000, 21:505-515.
Laird, A.D. et al. “SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors”Cancer Res, 2000, 60:4152-4160.
Lin, Q. et al. “Protein surface recognition by synthetic agents: Design and structural requirements of a family of artificial receptors that bind to cytochrome c”Biopoly, 1998, 47:285-297.
Lin, Q. and Hamilton, A. “Design and synthesis of multiple-loop receptors based on a calix[4]arene scaffold for protein surface recognition”C.R. Chimie, 2002, 5:441-450.
Miao, R.Q. et al. “Kallistatin is a new inhibitor of angiogenesis and tumor growth”Blood, 2002, 100:3245-3252.
Morin, M.J. “From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents”Oncogene, 2000, 19:6574-6583.
Oefner, C. et al. “Crystal structure of human platelet-derived growth factor BB”Embo J, 1992, 11:3921-3926.
Sebti, S. and Hamilton, A.D. “Design of growth factor antagonists with antiangiogenic and antitumor properties”Oncogene, 2000, 19(56):6566-6573.
Sun, J. et al. “Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors”Oncogene, 2005, 24:4701-4709.
Sun, J. et al. “Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor”Cancer Res, May 15, 2004, 64(10):3586-3592.
Sun, J. et al. “Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors” presented at Annual Meeting of the American Association for Cancer Research, Mar. 26-30, 2004, Orlando, FL, abstract No. 4533.
Wedge, S.R. et al. “ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy”Cancer Res, 2000, 60:970-975.
Zhang, W. et al. “A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model”Angiogenesis, 2002, 5:35-44.
International Search Report PCT/US01/08920, dated Aug. 31, 2001.
Bach, A.C. et al. “Structural studies of a family of high affinity ligands for GPIlb/IIIa”J. Am. Chem. Soc., 1994, 116:3207-3219.
Blaskovich, M.A. et al. “Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice”Nature Biotech., 2000, 18:1065-1070.
Hamuro, Y. et al. “A calixarene with four peptide loops: an antibody mimic for recognition of protein surfaces”Agnew. Chemie Int. Ed. Engl., 1997, 36:2680-2683.
Park, H.D. et al. “Protein surface recognition by synthetic receptors: a route to novel sub-micromolar inhibitors for chymotrypsin”J. Am. Chem. Soc., 1999, 121:8-13.
Shuker, S.B. et al. “Solid-phase synthesis of a novel peptide substituted calyx[4]arene”Synlett, 2001, 2:210-213.
Wilson, I.A. et al. “Structural aspects of antibodies and antibody-antigen complexes”Ciba Foundation Symp., 1991, 159:13-39.

Affiliated with

Also associated with

Rating

Growth factor binding molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Growth factor binding molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Growth factor binding molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4146711